Ryan C. Lynch

7.3k total citations · 1 hit paper
104 papers, 3.9k citations indexed

About

Ryan C. Lynch is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Ryan C. Lynch has authored 104 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pathology and Forensic Medicine, 52 papers in Oncology and 29 papers in Genetics. Recurrent topics in Ryan C. Lynch's work include Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (29 papers) and CAR-T cell therapy research (23 papers). Ryan C. Lynch is often cited by papers focused on Lymphoma Diagnosis and Treatment (53 papers), Chronic Lymphocytic Leukemia Research (29 papers) and CAR-T cell therapy research (23 papers). Ryan C. Lynch collaborates with scholars based in United States, South Africa and Spain. Ryan C. Lynch's co-authors include Steven K. Schmidt, John L. Darcy, Diana R. Nemergut, Joseph E. Knelman, Sean O’Neill, Scott Ferrenberg, Teresa Bilinski, Lee F. Stanish, Tadashi Fukami and Sandra Ryeom and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Ryan C. Lynch

93 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Patterns and Processes of Microbial Community Assembly

2013 1.4k citations Diana R. Nemergut, Steven K. Schmidt et al. Microbiology and Molecular Biology Reviews profile →

Peers

Countries citing papers authored by Ryan C. Lynch

Since Specialization

Citations

This map shows the geographic impact of Ryan C. Lynch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan C. Lynch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan C. Lynch more than expected).

Fields of papers citing papers by Ryan C. Lynch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan C. Lynch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan C. Lynch. The network helps show where Ryan C. Lynch may publish in the future.

Co-authorship network of co-authors of Ryan C. Lynch

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan C. Lynch. A scholar is included among the top collaborators of Ryan C. Lynch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan C. Lynch. Ryan C. Lynch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of immunophenotype on clinical disease characteristics and outcomes in T‐cell prolymphocytic leukaemia 2025 ·British Journal of Haematology ·Christina Poh, Xueyan Chen, Jenna Voutsinas, Kikkeri N. Naresh, (unknown), Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, (unknown), Edus H. Warren, Stephen D. Smith, Qian Wu, Sindhu Cherian, Ajay K. Gopal	0
2	Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas 2025 ·Blood Advances ·Christina Poh, Jenna Voutsinas, Mazyar Shadman, Ryan C. Lynch, Edus H. Warren, (unknown), Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Wu, Michi M. Shinohara, Ajay K. Gopal	1
3	Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma 2025 ·Journal of Clinical Oncology ·Mark Roschewski, David M. Kurtz, Jason R. Westin, Ryan C. Lynch, Ajay K. Gopal, Stefan Alig, Brian J. Sworder, (unknown), Christian Kuffer, Derek Blair, Krystal Brown, Jordan Goldstein, André Schultz, Sandra Close, Jacob J. Chabon, Maximilian Diehn, Wyndham H. Wilson, Ash A. Alizadeh	0
4	Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis 2024 ·Transplantation and Cellular Therapy ·Christina Poh, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Edus H. Warren, Mazyar Shadman, Brian G. Till, (unknown), Jordan Gauthier, Alexandre V. Hirayama, Stephen D. Smith, Taranjit S. Gujral, Chihiro Morishima, (unknown), Jenna Voutsinas, (unknown), David G. Maloney, Ajay K. Gopal	0
5	Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma 2024 ·Seminars in Radiation Oncology ·Ryan C. Lynch, Michael S. Binkley	1
6	Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma 2024 ·British Journal of Haematology ·(unknown), Ryan C. Lynch	3
7	Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up 2024 ·Blood ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, (unknown), Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna Voutsinas, Ajay K. Gopal	1
8	Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL 2024 ·Blood ·Jordan Goldstein, Mark Roschewski, Won-Seog Kim, Sang Eun Yoon, (unknown), Jason R. Westin, Ryan C. Lynch, Stefan Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H. Wilson, David M. Kurtz, Ash A. Alizadeh	0
9	MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS 2023 ·Hematological Oncology ·Mark Roschewski, David M. Kurtz, Jason R. Westin, Ryan C. Lynch, Stefan Alig, Calum MacAulay, Christian Kuffer, (unknown), André Schultz, Sandra Close, (unknown), Davide Rossi, Stephen Opat, Rodney J. Hicks, Mark Hertzberg, Maximilian Diehn, Wyndham H. Wilson, Ash A. Alizadeh	5
10	Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study 2023 ·EClinicalMedicine ·Marek Trněný, Abraham Avigdor, Matthew McKinney, Shankara Paneesha, Björn E. Wahlin, John Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos‐Oreiro, David Belada, Liliana Devizzi, (unknown), Douglas J. DeMarini, Wei Jiang, Ping Jiang, Ryan C. Lynch	3
11	Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors 2023 ·Blood ·(unknown), (unknown), Ryan C. Lynch, (unknown), Christine D Crider, (unknown), (unknown), Stephanie Louie, David G. Maloney, Christina Poh, Brian G. Till, Stephen D. Smith, Ajay K. Gopal, Chaitra S. Ujjani, Mazyar Shadman	0
12	Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis 2023 ·Blood ·Christina Poh, Victor A. Chow, Ryan C. Lynch, Chaitra S. Ujjani, Mazyar Shadman, Brian G. Till, (unknown), Edus H. Warren, Jordan Gauthier, Stephen D. Smith, Taranjit S. Gujral, Chihiro Morishima, Qian Wu, Jenna Voutsinas, (unknown), (unknown), David G. Maloney, Ajay K. Gopal	1
13	Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up 2023 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian Wu, Jenna Voutsinas, (unknown), (unknown), Chaitra S. Ujjani, Ryan D. Cassaday, Jonathan R. Fromm, Min Fang, Stephen D. Smith	5
14	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study 2021 ·The Lancet Haematology ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, (unknown), (unknown), (unknown), Karolyn Morris, Heather Rasmussen, Fatemeh Behnia, Jenna Voutsinas, Ajay K. Gopal	33
15	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Solomon A. Graf, Ryan D. Cassaday, Karolyn Morris, Jenna Voutsinas, Qian Wu, Fatemeh Behnia, Ryan C. Lynch, Elizabeth F. Krakow, Heather Rasmussen, Thomas R. Chauncey, Sandra Kanan, Lorinda Soma, Stephen D. Smith, Ajay K. Gopal	10
16	Clinical Impact of the 2016 Update to the WHO Lymphoma Classification 2017 ·Current Treatment Options in Oncology ·Ryan C. Lynch, Dita Gratzinger, Ranjana H. Advani	31
17	Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation 2017 ·Case Reports in Oncology ·Ryan C. Lynch, Ranjana H. Advani	1
18	Genomic and Chemical Diversity in Cannabis 2016 ·Critical Reviews in Plant Sciences ·Ryan C. Lynch, Daniela Vergara, Silas Tittes, (unknown), Christopher Schwartz, (unknown), Travis C. Ruthenburg, (unknown), (unknown), Nolan C. Kane	104
19	Patterns and Processes of Microbial Community Assembly breakdown → 2013 ·Microbiology and Molecular Biology Reviews ·Diana R. Nemergut, Steven K. Schmidt, Tadashi Fukami, Sean O’Neill, Teresa Bilinski, Lee F. Stanish, Joseph E. Knelman, John L. Darcy, Ryan C. Lynch, (unknown), Scott Ferrenberg	1361
20	Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch 2006 ·Proceedings of the National Academy of Sciences ·Sylvie Giuriato, Sandra Ryeom, Alice C. Fan, Pavan Bachireddy, Ryan C. Lynch, Matthew J. Rioth, Jan van Riggelen, (unknown), Emmanuelle Passegué, Flora Tang, Judah Folkman, Dean W. Felsher	115

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact